Profile data is unavailable for this security.
About the company
Refocus Group, Inc. is a medical device company. The Company is involved in researching and developing treatments for human vision disorders, particularly for the treatment of presbyopia. The Company’s product, VisAbility Micro Insert System, is a binocular presbyopia treatment, which works outside the visual axis. VisAbility Micro Insert System is under clinical trials in the United States and aims to help patients reduce or eliminate their need for reading glasses.
- Revenue in USD (TTM)0.00
- Net income in USD-4.77m
- Incorporated2003
- Employees4.00
- LocationRefocus Group Inc9155 Sterling Street, Suite 160IRVING 75063United StatesUSA
- Phone+1 (972) 893-1008
- Fax+1 (302) 655-5049
- Websitehttps://www.refocus-group.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shengtai Pharmaceutical Inc | -100.00bn | -100.00bn | 10.00 | 733.00 | -- | 0.00 | -- | -- | -- | -- | -- | 6.71 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.343 | -- | 0.5848 | -- | -- | -- | -- | -- | -- | -- |
| Refocus Group Inc | 0.00 | -4.77m | 20.00 | 4.00 | -- | -- | -- | -- | -0.1961 | -0.1961 | 0.00 | 0.0574 | 0.00 | 0.00 | -- | 0.00 | -140.63 | -- | -205.65 | -- | -- | -- | -- | -- | 3.08 | -44.01 | 0.00 | -- | -- | -- | 32.59 | -- | -- | -- |
| Altrazeal Life Sciences Inc | 568.75k | -2.20m | 20.00 | 7.00 | -- | 0.00 | -- | 0.00004 | -0.1093 | -0.1093 | 0.0282 | 0.2154 | 0.0689 | 0.3993 | 3.38 | -- | -26.67 | -45.42 | -36.70 | -77.20 | 67.69 | 62.08 | -387.26 | -423.73 | 1.29 | -3.56 | 0.1618 | -- | 62.04 | 14.12 | 56.52 | -- | -44.14 | -- |
| Tetralogic Pharmaceuticals Corp | 0.00 | -40.72m | 20.00 | 29.00 | -- | -- | -- | -- | -1.64 | -1.64 | 0.00 | -1.25 | 0.00 | -- | -- | 0.00 | -59.95 | -- | -69.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -38.28 | -- | -- | -- |
Data as of Feb 23 2024. Currency figures normalised to Refocus Group Inc's reporting currency: US Dollar USD
